Sykes, M., & Sachs, D. H. (2022). Progress in xenotransplantation: overcoming immune barriers. Nature Reviews Nephrology, 18(12), 745–761. https://doi.org/10.1038/s41581-022-00624-6

Wei, A. Z., Maniar, A. B., & Carvajal, R. D. (2022). New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma. Cancer Gene Therapy, 29(12), 1819–1826. https://doi.org/10.1038/s41417-022-00443-8

Keshavjee, S. H., Moy, R. H., Reiner, S. L., Ryeom, S. W., & Yoon, S. S. (2022). Gastric Cancer and the Immune System: The Key to Improving Outcomes? Cancers, 14(23), 5940. https://doi.org/10.3390/cancers14235940

Zeidan, A. M., Platzbecker, U., Garcia-Manero, G., Sekeres, M. A., Fenaux, P., DeZern, A. E., Greenberg, P. L., Savona, M. R., Jurcic, J. G., Verma, A. K., Mufti, G. J., Buckstein, R., Santini, V., Shetty, J. K., Ito, R., Zhang, J., Zhang, G., Ha, X., Backstrom, J. T., & Komrokji, R. S. (2022). Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood, 140(20), 2170–2174. https://doi.org/10.1182/blood.2022016171

Wang, M. L., Shah, N. N., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I. W., Tessoulin, B., Alencar, A. J., Ma, S., Lech-Marańda, E., Rhodes, J. M., Patel, K., Woyach, J. A., Lamanna, N., … Mato, A. R. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 9368–9372. https://doi.org/10.1182/blood-2022-159425

Lim, E. A., Bendell, J. C., Falchook, G. S., Bauer, T. M., Drake, C. G., Choe, J. H., George, D. J., Karlix, J. L., Ulahannan, S., Sachsenmeier, K. F., Russell, D. L., Moorthy, G., Sidders, B. S., Pilling, E. A., Chen, H., Hattersley, M. M., Das, M., Kumar, R., Pouliot, G. P., & Patel, M. R. (2022). Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research, 28(22), 4871–4884. https://doi.org/10.1158/1078-0432.ccr-22-0612

Chakraborty, R., Behera, T. R., Li, H., Dean, R. M., Hill, B. T., Jagadeesh, D., Winter, A., Anwer, F., Pohlman, B., Sobecks, R. M., Hamilton, B. K., & Majhail, N. S. (2022). Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study. Blood, 140(Supplement 1), 10926–10927. https://doi.org/10.1182/blood-2022-166904

Frangoul, H., Locatelli, F., Bhatia, M., Mapara, M. Y., Molinari, L., Sharma, A., Lobitz, S., de Montalembert, M., Rondelli, D., Steinberg, M., Walters, M. C., Imren, S., Zhang, L., Sharma, A., Song, Y., Simard, C., Hobbs, W., & Grupp, S. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Blood, 140(Supplement 1), 29–31. https://doi.org/10.1182/blood-2022-162353

Naqvi, S. A. A., Fatima, S., Asghar, N., Ijaz, H., Ayaz, A., He, H., Husnain, M., Chakraborty, R., Riaz, I., & Aljama, M. A. (2022). Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis. Blood, 140(Supplement 1), 10111–10113. https://doi.org/10.1182/blood-2022-170869

Li, S., Fu, J., Yang, J., Ma, H., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2022). MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism. Blood, 140(Supplement 1), 4224–4225. https://doi.org/10.1182/blood-2022-168314

Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L. C., Izutsu, K., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., & Horwitz, S. M. (2022). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis. Blood, 140(Supplement 1), 9387–9389. https://doi.org/10.1182/blood-2022-169432

Zhou, P., Mansukhani, M. M., Toskic, D., Scalia, S., Lee, L., Wong, S. W., Tuchman, S. A., Hoffman, J. E., Fogaren, T., Varga, C., Lentzsch, S., & Comenzo, R. (2022). Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM). Blood, 140(Supplement 1), 10048–10049. https://doi.org/10.1182/blood-2022-157790

Orlando, E., Ford, M., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation. Blood, 140(Supplement 1), 12085–12086. https://doi.org/10.1182/blood-2022-158050

Bumma, N., Richter, J., Brayer, J., Zonder, J. A., Dhodapkar, M., Shah, M. R., Hoffman, J. E., Mawad, R., Maly, J. J., Lentzsch, S., Suvannasankha, A., Roy, P., Dey, J., Chokshi, D., Boyapati, A., Visich, J., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., & Jagannath, S. (2022). Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study. Blood, 140(Supplement 1), 10140–10141. https://doi.org/10.1182/blood-2022-159969

Chakraborty, R., Sexton, R., Lentzsch, S., Abidi, M. H., Voorhees, P. M., Cohen, A. D., Rohren, E., Heitner, S. B., Kelly, K. R., Mackler, N. J., Baer, D. M., Hoering, A., Durie, B. G. M., Ailawadhi, S., & Orlowski, R. Z. (2022). Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib. Blood, 140(Supplement 1), 4349–4351. https://doi.org/10.1182/blood-2022-166609

Estrella, B., Pazos, M. A., Ricker, E. C., Ryu, Y. K., Piorczynski, T. B., Liu, Y., Tolu, S., & Amengual, J. E. (2022). First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade. Blood, 140(Supplement 1), 358–359. https://doi.org/10.1182/blood-2022-166929

Lee, H. J., Choi, M. Y., Siddiqi, T., Rhodes, J. M., Wierda, W. G., Isufi, I., Tuscano, J. M., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, M., Jamieson, C., & Kipps, T. J. (2022). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood, 140(Supplement 1), 566–568. https://doi.org/10.1182/blood-2022-167153

Mosialou, I., Ali, A. M., Adams, R., Corper, A., Woods, C. M., Fan, X., Raza, A., & Kousteni, S. (2022). Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance. Blood, 140(Supplement 1), 2902–2902. https://doi.org/10.1182/blood-2022-167042

Walters, M. C., Thompson, A. A., Kwiatkowski, J. L., Parikh, S., Mapara, M. Y., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Miller, A., Zhang, L., Chawla, A., Macari, E. R., Pierciey, F. J., Tisdale, J. F., & Kanter, J. (2022). Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study. Blood, 140(Supplement 1), 26–28. https://doi.org/10.1182/blood-2022-162288

Melody, M., St. Pierre, F., Helenowski, I., Pearse, W. B., Vakkalagadda, C. V., Leventhal, J. R., Friedewald, J., Ho, B., Ganger, D., Winter, J. N., Gordon, L. I., Lin, A. Y., Karmali, R., Ma, S., Pro, B., & Moreira, J. (2022). Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 6674–6675. https://doi.org/10.1182/blood-2022-164724

Mahadeo, K. M., Baiocchi, R. A., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Nikiforow, S., Reshef, R., Ye, W., & Prockop, S. (2022). New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood, 140(Supplement 1), 10374–10376. https://doi.org/10.1182/blood-2022-157766

Melody, M., St. Pierre, F., Helenowski, I., Pearse, W. B., Vakkalagadda, C., Leventhal, J. R., Ho, B., Friedewald, J., Ganger, D., Winter, J. N., Gordon, L. I., Lin, A. Y., Karmali, R., Ma, S., Pro, B., & Moreira, J. (2022). Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD. Blood, 140(Supplement 1), 3833–3834. https://doi.org/10.1182/blood-2022-167812

Granat, L. M., Li, H., Anwer, F., Sheu, M., Faiman, B. M., Khouri, J., Mazzoni, S., Valent, J., Samaras, C. J., Chakraborty, R., Chaulagain, C. P., van Heeckeren, W. J., & Williams, L. S. (2022). Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma. Blood, 140(Supplement 1), 4290–4291. https://doi.org/10.1182/blood-2022-168040

Wierda, W. G., Lewis, D. J., Ghia, P., Shah, N. N., Coombs, C. C., Cheah, C. Y., Lamanna, N., Rhodes, J. M., Hoffmann, M., Ma, S., Eyre, T. A., Munir, T., Patel, M. R., Alencar, A. J., Tam, C. S., Seymour, J. F., Jurczak, W., Lech-Marańda, E., Roeker, L. E., … Mato, A. R. (2022). Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 846–849. https://doi.org/10.1182/blood-2022-157058

Blachly, J. S., Stephens, D. M., Ye, J. C., Lamanna, N., Jain, N., Niesman, M., Zhang, K., & Woyach, J. A. (2022). Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL. Blood, 140(Supplement 1), 2324–2325. https://doi.org/10.1182/blood-2022-171203

Breyer, L. M., Wang, H., Gu, D., Johnstone, B. H., Ma, H., Woods, E. J., & Mapara, M. Y. (2022). Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice. Blood, 140(Supplement 1), 7347–7348. https://doi.org/10.1182/blood-2022-169787

Ford, M., Orlando, E., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 3794–3795. https://doi.org/10.1182/blood-2022-163813

Capellini, A., Etra, A., Alousi, A. M., Al Malki, M. M., Choe, H., Defilipp, Z., Hogan, W. J., Kitko, C. L., Ayuk, F. A., Baez, J., Gandhi, I., Kasikis, S., Gleich, S., Hexner, E. O., Hoepting, M., Kapoor, U., Kowalyk, S., Kwon, D., Langston, A., … Levine, J. E. (2022). Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy. Blood, 140(Supplement 1), 1867–1869. https://doi.org/10.1182/blood-2022-156000

Thomas, T., Qiu, A., Kim, C. Y., Gordy, D. E., Miller, A., Tredicine, M., Stone, E., Dzieciatkowska, M., Hod, E. A., D’Alessandro, A., Spitalnik, S. L., Zimring, J. C., Akpan, I. J., Luckey, C. J., & Hudson, K. E. (2022). Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels. Blood, 140(Supplement 1), 75–76. https://doi.org/10.1182/blood-2022-169746

Ford, M., Orlando, E., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 3777–3778. https://doi.org/10.1182/blood-2022-160147

Di Meo, F., Iyer, A., Akama, K., Yu, C., Cheng, R., Cesarano, A., Marino, S., Aljoufi, A., Soni, R., Roda, J. M., Sissons, J., Vu, L. P., Guzman, M. L., Huang, K., Roodman, D. G., & Perna, F. (2022). A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma. Blood, 140(Supplement 1), 671–672. https://doi.org/10.1182/blood-2022-167584

Platzbecker, U., Komrokji, R. S., Fenaux, P., Zeidan, A. M., Sekeres, M. A., Savona, M. R., Madanat, Y. F., Santini, V., Van Eygen, K., Raza, A., Germing, U., Berry, T., Dougherty, S., Shah, S., Sun, L., Huang, F., Feller, F., Wan, Y., Ikin, A., & Sherman, L. (2022). Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study. Blood, 140(Supplement 1), 1106–1108. https://doi.org/10.1182/blood-2022-169050

Locatelli, F., Lang, P., Li, A., Corbacioglu, S., de la Fuente, J., Wall, D. A., Liem, R., Meisel, R., Mapara, M. Y., Shah, A. J., Cappellini, M. D. D., Kattamis, A., Sheth, S., Bobruff, Y., Bower, L., Zhang, L., Sharma, A., Song, Y., Hobbs, W., & Frangoul, H. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. Blood, 140(Supplement 1), 4899–4901. https://doi.org/10.1182/blood-2022-166881

Roy, I., Epperla, N., Shouse, G., Romancik, J. T., Moyo, T. K., Kenkre, V. P., Ollila, T. A., Fitzgerald, L. A., Hess, B. T., Evens, A. M., Zurko, J., Chowdhury, S. M., Annunzio, K., Ferdman, R., Bhansali, R. S., Harris, E. I., Sorrell, M., Liu, J., Nizamuddin, I. A., … Karmali, R. (2022). Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy. Blood, 140(Supplement 1), 2416–2418. https://doi.org/10.1182/blood-2022-163822

Mian, A., Wei, W., Chakraborty, R., Yi, J. C., Preussler, J. M., Hill, B. T., Cerny, J., Deol, A., Hahn, T. E., Hashmi, S. K., Jaglowski, S., Jim, H. S. L., Khera, N., Loren, A. W., McGuirk, J. P., Savani, B. N., Stiff, P., Uberti, J. P., Whalen, V., … Majhail, N. S. (2022). Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions. Blood, 140(Supplement 1), 8019–8021. https://doi.org/10.1182/blood-2022-167411

Mohyuddin, G. R., Chakraborty, R., Calip, G., Ascha, M. S., Wang, X., Rubinstein, S., Tuchman, S. A., Costa, L. J., Haaland, B., Giri, S., Mian, H. S., Fonseca, R., & Sborov, D. W. (2022). Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy. Blood, 140(Supplement 1), 5223–5224. https://doi.org/10.1182/blood-2022-165541

McCurdy, A., Seow, H., Pond, G. R., Gayowsky, A., Chakraborty, R., Visram, A., Kaedbey, R., D’Souza, A., Mohyuddin, G. R., Fonseca, R., & Mian, H. S. (2022). Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada. Blood, 140(Supplement 1), 427–429. https://doi.org/10.1182/blood-2022-157815

Fu, J., Li, S., Ma, H., Yang, J., Brown, L. M., Pagnotti, G. M., Weiss, S. J., Mapara, M. Y., & Lentzsch, S. (2022). The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease. Blood, 140(Supplement 1), 9930–9932. https://doi.org/10.1182/blood-2022-169921

Scalia, S., Toskic, D., Zhou, P., Mansukhani, M. M., Lee, L., Wong, S. W., Tuchman, S. A., Hoffman, J. E., Fogaren, T., Varga, C., Lentzsch, S., & Comenzo, R. (2022). The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients. Blood, 140(Supplement 1), 10120–10121. https://doi.org/10.1182/blood-2022-162352

Usmani, S., Patel, K., Hari, P., Berdeja, J., Alsina, M., Vij, R., Raje, N., Leleu, X., Dhodapkar, M., Reshef, R., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Ananthakrishnan, R., Greggio, C., Favre-Kontula, L., Sternas, L., & San-Miguel, J. (2022). KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. Blood, 140(Supplement 1), 875–877. https://doi.org/10.1182/blood-2022-162469

Shah, N. N., Wang, M. L., Brown, J. R., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Gastinne, T., Ghia, P., Lamanna, N., Hoffmann, M., Patel, M. R., Flinn, I. W., Gerson, J. N., Ma, S., Coombs, C. C., … Mato, A. R. (2022). Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 4127–4132. https://doi.org/10.1182/blood-2022-159035

Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Marańda, E., Lamanna, N., Tam, C. S., Seymour, J. F., Shah, N. N., Coombs, C. C., Ujjani, C. S., Patel, M. R., Fakhri, B., Cheah, C. Y., Alencar, A. J., Cohen, J. B., … Jurczak, W. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 2316–2320. https://doi.org/10.1182/blood-2022-159497

Hershman, D. L., Unger, J. M., Greenlee, H., Capodice, J., Lew, D. L., Darke, A., Minasian, L. M., Fisch, M. J., Henry, N. L., & Crew, K. D. (2022). Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain. JAMA Network Open, 5(11), e2241720. https://doi.org/10.1001/jamanetworkopen.2022.41720

Van Egeren, D., Kohli, K., Warner, J. L., Bedard, P. L., Riely, G., Lepisto, E., Schrag, D., LeNoue-Newton, M., Catalano, P., Kehl, K. L., Michor, F., Fiandalo, M., Foti, M., Khotskaya, Y., Lee, J., Peters, N., Sweeney, S., Abraham, J., … Walther, Z. (2022). Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-21448-1

Neugut, A. I. (2022). Cancer as a Disease of the Cell. The Oncologist, 27(11), 901–902. https://doi.org/10.1093/oncolo/oyac152

Liao, C.-Y., Johnson, B., Spira, A., Carbone, D., Henick, B., Overman, M., Polite, B., Roychowdhury, S., Mahipal, A., Ahn, D., Johnson, M., Schenk, D., Bae, K., Davis, M., Jooss, K., Ferguson, A., & Solomon, B. (2022). 660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen. Regular and Young Investigator Award Abstracts, A691–A691. https://doi.org/10.1136/jitc-2022-sitc2022.0660

Stein, M., Goodman, O., Dorff, T., Narayan, V., Avitia, J., McKay, R., Nordquist, L., Rettig, M., Schweizer, M., Thomas, R., Silverman, M., Yao, L., Clynes, R., & Shorr, J. (2022). 668 A phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. Regular and Young Investigator Award Abstracts, A698–A698. https://doi.org/10.1136/jitc-2022-sitc2022.0668

Kinslow, C. J., DeStephano, D. M., Rohde, C. H., Kachnic, L. A., Cheng, S. K., Neugut, A. I., & Horowitz, D. P. (2022). Risk of Anaplastic Large Cell Lymphoma Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Ductal Carcinoma in Situ. JAMA Network Open, 5(11), e2243396. https://doi.org/10.1001/jamanetworkopen.2022.43396

Trivedi, M. S., Arber, N., Friedman, E., Garber, J. E., Holcomb, K., Horowitz, N. S., Wright, J. D., Lee, J. J., Vornik, L. A., Abutaseh, S., Castile, T., Sauter, E. R., Dimond, E., Heckman-Stoddard, B. M., House, M., Samimi, G., Brown, P. H., & Crew, K. D. (2022). Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy. Cancer Prevention Research, 15(11), 721–726. https://doi.org/10.1158/1940-6207.capr-22-0051

Coutinho, D. F., Mundi, P. S., Marks, L. J., Burke, C., Ortiz, M. V., Diolaiti, D., Bird, L., Vallance, K. L., Ibáñez, G., You, D., Long, M., Rosales, N., Grunn, A., Ndengu, A., Siddiquee, A., Gaviria, E. S., Rainey, A. R., Fazlollahi, L., Hosoi, H., … Dela Cruz, F. S. (2022). Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. Med, 3(11), 774-791.e7. https://doi.org/10.1016/j.medj.2022.09.002